Excitatory amino acids as therapeutic agents: Reversing neurodegenerative trajectory by tackling excitotoxicity.

Autor: Dhurandhar Y; Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur Chhattisgarh, 495009, India., Tomar S; National Coordination Centre, Pharmacovigilance Programme of India, Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, Government of India, Sector 23, Rajnagar, Ghaziabad, 201002, Uttar Pradesh, India. subhamt227@gmail.com., Namdeo KP; Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur Chhattisgarh, 495009, India., Bodakhe SH; Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur Chhattisgarh, 495009, India.
Jazyk: angličtina
Zdroj: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology [Neurol Sci] 2024 Nov 15. Date of Electronic Publication: 2024 Nov 15.
DOI: 10.1007/s10072-024-07880-3
Abstrakt: Neurodegenerative diseases pose significant challenges to healthcare systems globally due to their complex etiology and relentless progression, often rendering conventional treatments ineffective. Recent advances have spotlighted excitatory amino acids, particularly D-amino acids, once considered as products of metabolism of the microbiota or deriving from food intake. This review explores the role of D-amino acids in mitigating excitotoxicity-a process characterized by excessive calcium influx through aberrant N-methyl-D-aspartate receptor (NMDAR) activation, which is implicated in the pathogenesis of diseases like Alzheimer's disease. By providing alternative pathways for neuronal signaling and protecting against excitotoxic damage, D-amino acids offer a novel approach to reversing neurodegenerative trajectories. Future research should focus on elucidating the detailed mechanisms of action of these compounds, evaluating their therapeutic potential through rigorous preclinical and clinical trials, and developing effective delivery systems to optimize their neuroprotective effects. This emerging field holds promise for developing innovative treatment strategies that could significantly improve outcomes for patients with neurodegenerative disorders.
Competing Interests: Declarations All authors read and approved the manuscript, and the manuscript has not been submitted elsewhere nor published in whole or in part. Ethical approval Not applicable. Human and animal rights Not applicable. Informed consent Not applicable. Conflict of interests The authors have no relevant financial or non-financial interests to disclose. Competing interests The authors declare no conflict of interest.
(© 2024. Fondazione Società Italiana di Neurologia.)
Databáze: MEDLINE
Externí odkaz: